Faculty Opinions recommendation of Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Dna Vaccine ◽

Double Blind ◽

Double Blind Placebo ◽

Human Papillomavirus 16 ◽

Synthetic Dna ◽

E6 And E7 ◽

E7 Proteins

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet ◽

10.1016/s0140-6736(15)00239-1 ◽

2015 ◽

Vol 386 (10008) ◽

pp. 2078-2088 ◽

Cited By ~ 305

Author(s):

Cornelia L Trimble ◽

Matthew P Morrow ◽

Kimberly A Kraynyak ◽

Xuefei Shen ◽

Michael Dallas ◽

...

Keyword(s):

Human Papillomavirus ◽

Dna Vaccine ◽

Double Blind ◽

Double Blind Placebo ◽

Human Papillomavirus 16 ◽

Synthetic Dna ◽

E6 And E7 ◽

E7 Proteins

Cytotoxic T Lymphocyte Responses to E6 and E7 Proteins of Human Papillomavirus Type 16: Relationship to Cervical Intraepithelial Neoplasia

The Journal of Infectious Diseases ◽

10.1086/513992 ◽

1997 ◽

Vol 175 (4) ◽

pp. 927-931 ◽

Cited By ~ 107

Author(s):

Mayumi Nakagawa ◽

Daniel P. Stites ◽

Sepideh Farhat ◽

Jerry R. Sisler ◽

Bernard Moss ◽

...

Keyword(s):

Human Papillomavirus ◽

T Lymphocyte ◽

Cytotoxic T Lymphocyte ◽

Human Papillomavirus Type 16 ◽

E6 And E7 ◽

E7 Proteins ◽

Lymphocyte Responses

Abstract CT209: Safety, efficacy and immunogenicity of VB10.16, a therapeutic DNA vaccine targeting human papillomavirus (HPV) 16 E6 and E7 proteins for high grade cervical intraepithelial neoplasia (CIN 2/3): 6-month data from an exploratory open-label phase I/2a trial

10.1158/1538-7445.am2019-ct209 ◽

2019 ◽

Author(s):

Peter Hillemanns ◽

Karl Ulrich Petry ◽

Linn Woelber ◽

Gerd Böhmer ◽

Elisabeth Stubsrud ◽

...

Keyword(s):

Human Papillomavirus ◽

Phase I ◽

Dna Vaccine ◽

High Grade ◽

Open Label ◽

Open Label Phase ◽

E6 And E7 ◽

E7 Proteins ◽

Therapeutic Dna Vaccine

Abstract CT209: Safety, efficacy and immunogenicity of VB10.16, a therapeutic DNA vaccine targeting human papillomavirus (HPV) 16 E6 and E7 proteins for high grade cervical intraepithelial neoplasia (CIN 2/3): 6-month data from an exploratory open-label phase I/2a trial

10.1158/1538-7445.sabcs18-ct209 ◽

2019 ◽

Cited By ~ 1

Author(s):

Peter Hillemanns ◽

Karl Ulrich Petry ◽

Linn Woelber ◽

Gerd Böhmer ◽

Elisabeth Stubsrud ◽

...

Keyword(s):

Human Papillomavirus ◽

Phase I ◽

Dna Vaccine ◽

High Grade ◽

Open Label ◽

Open Label Phase ◽

E6 And E7 ◽

E7 Proteins ◽

Therapeutic Dna Vaccine

DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-2-s3-o17 ◽

2014 ◽

Vol 2 (S3) ◽

Author(s):

Laurent Humeau ◽

◽

Cornelia Trimble ◽

Matthew Morrow ◽

Xuefei Shen ◽

...

Keyword(s):

T Cell ◽

Dna Vaccine ◽

Phase Ii ◽

Phase Ii Trial ◽

Hpv Infection ◽

Double Blind ◽

Double Blind Placebo ◽

Cell Responses

Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort

Journal of Translational Medicine ◽

10.1186/1479-5876-12-44 ◽

2014 ◽

Vol 12 (1) ◽

pp. 44 ◽

Cited By ~ 15

Author(s):

Hanna-Mari Koskimaa ◽

Anna E Paaso ◽

Marij JP Welters ◽

Seija E Grénman ◽

Kari J Syrjänen ◽

...

Keyword(s):

Human Papillomavirus ◽

T Cell ◽

T Cell Responses ◽

Human Papillomavirus 16 ◽

Cell Responses ◽

E6 And E7

The association between human papillomavirus 16, 18 DNA load and E6 protein expression in cervical intraepithelial neoplasia and cancer

Journal of Clinical Virology ◽

10.1016/j.jcv.2018.08.008 ◽

2018 ◽

Vol 108 ◽

pp. 6-11

Author(s):

Zeni Wu ◽

Lulu Yu ◽

Xiaoqin Lei ◽

Yu Qin ◽

Xun Zhang ◽

...

Keyword(s):

Human Papillomavirus ◽

Protein Expression ◽

Human Papillomavirus 16 ◽

E6 Protein

Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative

Journal of Translational Medicine ◽

10.1186/s12967-015-0733-4 ◽

2015 ◽

Vol 13 (1) ◽

Cited By ~ 7

Author(s):

Hanna-Mari Koskimaa ◽

Anna Paaso ◽

Marij J. P. Welters ◽

Seija Grénman ◽

Kari Syrjänen ◽

...

Keyword(s):

Human Papillomavirus ◽

Cell Mediated Immunity ◽

Specific Cell ◽

Human Papillomavirus 16

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial

International Journal of Cancer ◽

10.1002/ijc.30391 ◽

2016 ◽

Vol 139 (12) ◽

pp. 2812-2826 ◽

Cited By ~ 41

Author(s):

Suzanne M. Garland ◽

Jorma Paavonen ◽

Unnop Jaisamrarn ◽

Paulo Naud ◽

Jorge Salmerón ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Human Papillomavirus ◽

Controlled Trial ◽

High Grade ◽

Human Papillomavirus 16 ◽

Post Hoc Analysis ◽

Randomized Controlled ◽

Post Hoc

Effects of Long-Term Vitamin D Supplementation on Regression and Metabolic Status of Cervical Intraepithelial Neoplasia: a Randomized, Double-Blind, Placebo-Controlled Trial

Hormones and Cancer ◽

10.1007/s12672-016-0278-x ◽

2017 ◽

Vol 8 (1) ◽

pp. 58-67 ◽

Cited By ~ 10

Author(s):

Zahra Vahedpoor ◽

Mehri Jamilian ◽

Fereshteh Bahmani ◽

Esmat Aghadavod ◽

Maryam Karamali ◽

...

Keyword(s):

Vitamin D ◽

Controlled Trial ◽

Vitamin D Supplementation ◽

Metabolic Status ◽

Double Blind ◽

Double Blind Placebo